U.S. FDA gives nod to first generic version of Eliquis tablets
Category: #health  By Mateen Dalal  Date: 2019-12-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

U.S. FDA gives nod to first generic version of Eliquis tablets

The U.S. FDA (Food and Drug Administration) has reportedly made headlines after it recently approved the first generic versions of Eliquis (apixaban) tablets in the U.S. The generic tablets are formulated to decrease the risk of stroke and systemic embolism with nonvalvular atrial fibrillation (AFib) patients.

These tablets are indicated for the prophylaxis of DVT (deep vein thrombosis) which may lead to PE (pulmonary embolism) in patients who have undergone knee or hip replacement surgery. They are also indicated for PE and DVT treatment to reduce the risk of recurrent PE and DVT following initial therapy. 

According to Janet Woodcock, M.D., Director at FDA’s Center Drug Evaluation and Research, said that the approval of the first generic versions of Eliquis is an example of how FDA’s generic drug program gives better access to safe, high quality and low-cost medicines. Woodcock added that this is the first generic approval of a direct oral anticoagulant.

Apparently, addressing generic drug development challenges and promoting generic drug competition is a vital part of the FDA’s Drug Competition Action Plan. Under this program, the agency is helping patients by giving access to affordable drugs. The approval was granted to Mylan Pharmaceuticals Inc. and Micro Labs Ltd, said the agency.

Meanwhile, reports cite that sales of Apixaban, which was co-developed by Bristol-Myers and Pfizer, rose around 22% to USD 1.93 billion and made up around 30% of the total revenue of Bristol-Myers in the last reported quarter. 

For the uninitiated, atrial fibrillation (AFib) is a heart rhythm issue that can potentially cause blood clots. According to CDC, between 2.7 million and 6.1 million people in the U.S. suffer from atrial fibrillation. Many of its patients use anti-clotting or anticoagulants drugs to reduce its risk.

Source Link - https://www.fda.gov/news-events/press-announcements/fda-approves-first-generics-eliquis

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Stocks of luxury fashion houses raise in response to China’s reopening
Stocks of luxury fashion houses raise in response to China’s reopening
By Mateen Dalal

Luxury fashion houses dependent on Chinese customers reportedly saw a hike in stocks as China reopens, however, those clients may not necessarily be purchasing the goods elsewhere. In the past, wealthy Chinese customers would frequently buy person...

Microsoft investigates Teams and Outlook outage that left users disrupted
Microsoft investigates Teams and Outlook outage that left users disrupted
By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

DeHaat secures $60 million in funding, tops $700 million valuation
DeHaat secures $60 million in funding, tops $700 million valuation
By Mateen Dalal

Indian agritech firm DeHaat has reportedly raised $60 million in a new funding round as it looks forward to strengthening its footprint in the country and touching break-even profitability in two years. For the unversed, the startup provides a range ...